Adjusting CA19-9 values with clinical stage and bilirubin to better predict survival of resectable pancreatic cancer patients: 5-year-follow-up of a single center

BACKGROUND: Pancreatic cancer mortality is growing every year, and radical resection is the most essential therapy strategy. It is critical to evaluate the long-term prognosis of individuals receiving radical surgery. CA19-9 is a biomarker for patient recurrence and survival, however obstructive jau...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zuowei, Zhao, Pengcheng, Wang, Zihe, Huang, Xing, Wu, Chao, Li, Mao, Wang, Li, Tian, Bole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372400/
https://www.ncbi.nlm.nih.gov/pubmed/35965560
http://dx.doi.org/10.3389/fonc.2022.966256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372400/
https://www.ncbi.nlm.nih.gov/pubmed/35965560
http://dx.doi.org/10.3389/fonc.2022.966256

Ejemplares similares